Completed PHASE1 INTERVENTIONAL 1-arm NCT01015703

Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of CoVaccine HT™ in Healthy Adult Volunteers

Sponsor: BTG International Inc.

Conditions Vaccine

Interventions CoVaccine HT

Updated 5 times since 2017 Last updated: Sep 9, 2014 Started: Nov 30, 2009 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01015703, this PHASE1 trial focuses on Vaccine and remains completed. Sponsored by BTG International Inc., it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BTG International Inc.

Data source: BTG International Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom